What is the treatment for a patient presenting with priapism?

Treatment of Priapism

Immediate Diagnostic Differentiation

The first critical step is to obtain a corporal blood gas immediately to distinguish ischemic from non-ischemic priapism, as this determines whether you are managing a true urological emergency or a condition that can be observed. 1

Corporal Blood Gas Values:

• Ischemic priapism: PO₂ <30 mmHg, PCO₂ >60 mmHg, pH <7.25 1, 2
• Non-ischemic priapism: PO₂ >90 mmHg, PCO₂ <40 mmHg, pH 7.40 1, 2

Physical Examination Findings:

• Ischemic: Completely rigid, tender corpora cavernosa with severe pain; glans and corpus spongiosum remain soft 1, 2
• Non-ischemic: Partial tumescence without full rigidity, typically painless 2, 3

---

Management of Ischemic Priapism (>95% of Cases)

Ischemic priapism lasting >4 hours is a urological emergency requiring immediate intracavernosal phenylephrine injection with corporal aspiration—this is first-line treatment regardless of underlying etiology including sickle cell disease or leukemia. 1, 3

First-Line Treatment Protocol:

Intracavernosal Phenylephrine + Aspiration/Irrigation:

• Use phenylephrine concentration of 100-500 mcg/mL 3
• Maximum dose: 1000 mcg within the first hour 3
• Aspirate blood from corpora cavernosa before and after injection 1
• Irrigation with or without aspiration should accompany phenylephrine 1, 3
• Success rate: 43-81% when aspiration and phenylephrine are combined 3

Duration-Based Risk Stratification:

The likelihood of permanent erectile dysfunction directly correlates with priapism duration: 2, 3

• <24 hours: Reasonable chance of preserving erectile function 3
• 24-36 hours: Significantly increased risk of permanent erectile dysfunction 2
• >36 hours: High likelihood of permanent erectile dysfunction with minimal chance of recovery 2

Second-Line Treatment (If Phenylephrine Fails):

Proceed to distal shunt procedures (e.g., Winter shunt, Ebbehoj procedure, or tunneling techniques) if detumescence is not achieved with pharmacologic therapy 1

Third-Line Treatment:

For prolonged ischemic priapism (>36 hours) with established corporal fibrosis, consider early penile prosthesis placement rather than continuing futile detumescence attempts. 1

---

Critical Management Principles for Special Populations

Sickle Cell Disease Patients:

Do NOT delay standard urologic management (phenylephrine + aspiration) to perform exchange transfusion—this is explicitly contraindicated as primary treatment. 1, 3

• Standard urologic intervention takes absolute priority 1, 3
• Exchange transfusion shows no evidence of faster resolution than natural history and delays effective treatment by 6+ hours 1
• Concurrent sickle cell interventions (hydration, analgesia) should occur alongside—not instead of—urologic treatment 1, 2
• If operative shunting is required, consider simple transfusion to raise hemoglobin to 9-10 g/dL before general anesthesia 1

Iatrogenic Priapism (Post-Intracavernosal Injection):

For prolonged erections <4 hours following intracavernosal injection therapy, administer intracavernosal phenylephrine immediately rather than observing. 1

• Erections from alprostadil alone are less likely to progress to ischemic priapism compared to papaverine/phentolamine combinations 1
• Partial (non-rigid) erections may be observed, but fully rigid erections require immediate phenylephrine 1
• Once duration exceeds 4 hours, manage according to standard acute ischemic priapism protocol 1, 2

---

Management of Non-Ischemic Priapism (5% of Cases)

Initial management is observation for up to 4 weeks, as non-ischemic priapism is NOT an emergency and resolves spontaneously in up to 62% of cases. 1, 3

Conservative Management:

• Apply ice and site-specific compression to injury site 1
• No immediate invasive intervention required 1, 3

If Priapism Persists and Patient Requests Treatment:

Selective arterial embolization using temporary absorbable materials (autologous clot, gelatin sponges) is the treatment of choice—avoid permanent materials like coils. 1

• Temporary embolization: 74% resolution rate, 5% erectile dysfunction rate 1
• Permanent embolization: 78% resolution rate, 39% erectile dysfunction rate 1
• Surgical ligation is last resort with 50% erectile dysfunction rate 1

Critical Pitfall to Avoid:

Do NOT perform aspiration with sympathomimetic injection for non-ischemic priapism—it has no therapeutic efficacy and may cause systemic adverse effects due to unregulated arterial inflow. 1

---

Prevention of Recurrent Ischemic Priapism

For patients with recurrent episodes, initiate preventative therapy using PDE5 inhibitors (tadalafil or sildenafil) as first-line, as they reduce frequency and duration with no negative side effects. 1

Alternative Preventative Options:

• Ketoconazole with prednisone 1, 3
• Hydroxyurea (specifically for sickle cell disease patients) 3
• Home self-injection of phenylephrine on as-needed basis (not preventative, but for acute episodes) 1

Mandatory Counseling:

Patients must be informed that hormonal regulators (ketoconazole, cyproterone acetate) may impair fertility and sexual function, causing fatigue, hot flashes, breast tenderness, mood changes, and erectile dysfunction. 1, 3

---

Key Clinical Pitfalls to Avoid

1. Never delay corporal blood gas analysis—this leads to delayed diagnosis and inappropriate treatment 2
2. Never use exchange transfusion as primary treatment in sickle cell patients—it delays effective urologic intervention by hours without proven benefit 1
3. Never use aspiration/sympathomimetics for non-ischemic priapism—it is ineffective and potentially harmful 1
4. Never wait beyond 4 hours to initiate treatment for ischemic priapism—smooth muscle edema begins at 6 hours with progressive irreversible damage 2
5. Never fail to obtain adequate drug history—directly question about erectile dysfunction treatments, antipsychotics, antidepressants, and recreational drugs 2